Navitoclax + MCL-1 inhibitor
Navitoclax + MCL-1 inhibitor has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Dec 23, 2022: “Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression”.
1 paper studies it1 findingUpdated
- 1 lab in 1 country
- Funders: KWF Kankerbestrijding and 4 more
- Animals1
What did studies of Navitoclax + MCL-1 inhibitor find?
1Studies of Navitoclax + MCL-1 inhibitor measured 1 outcome; the most studied are nevi (1 study).
Nevi
downin mice1
1 study
Nevi
downin mice1
Navitoclax + MCL-1 inhibitor decreases nevi in mice.
“topical application sufficient to eliminate nevi in male mice”
Animalstopicalmales
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Nature communications
Latest
Nature Communications
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Experiments in miceInterventions